You searched for "vascular"
New mouse model of diabetes mellitus
Diabetic retinopathy (DR) is a serious complication of diabetes. It is driven by the loss of pericytes, cells which control vascular function, due to excess formation of sugar alcohols by the enzyme aldose reductase (AR). AR has been shown to...
The Retinal Atlas (2nd Edition)
Those readers familiar with the first edition of The Retinal Atlas will appreciate the comprehensive nature of this publication, and this latest version incorporates retinal images generated by recently developed imaging technology. As the title suggests, this hardcover version is...
Data update for leading causes of CVI in England and Wales
In this article the authors present an epidemiological update, based on certifiable visual impairment (CVI) registration for figures for sight impairment (SI) in England and Wales from the last report of 2007-2008 to the current data for April 2012 to...
Transfected RPE cells inhibit AMD in rats
Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly. Wet AMD is characterised by choroidal neovascularisation, new vessels into the retina, leading to leakage and tissue damage. Many proangiogenic factors particularly vascular endothelial growth factor (VEGF)...
The choroid in pregnancy
During pregnancy there can be different types of ocular changes including a decrease in corneal sensitivity, increase in central corneal thickness and curvature, decrease in intraocular pressure, central serous chorioretinopathy and ocular blood flow. Advances in ophthalmic imaging devices has...
Contrast sensitivity in myopic eyes
A classification system has been proposed for myopic maculopathy: grade 0 (no myopic retinal lesions), grade 1 (tessellated fundus), grade 2 (diffuse chorioretinal atrophy (CRA)), grade 3 (patchy CRA), and grade 4 (macular atrophy). Tessellated fundus is defined as the...
Anti-VEGF injections and macular atrophy progression in patients with nAMD in remission
This is a retrospective study of 59 eyes with neovascuar age-related macular degeneration (nAMD) with at least 6-month remission, to determine the effect of continuing anti-VEGF injections on the progression of macular atrophy (MA) during remission of nAMD. Group 1...
Vision loss during Eylea treatment for AMD
This report investigated patients who lost more than two lines of vision despite periodic injections of aflibercept and explored the factors associated with vision loss. One hundred and ninety-six eyes were included in this study over a two year period....Neovascular AMD: fresh recommendations underline standards of best practice
The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...21st Century retinal laser treatment in the anti-VEGF era
In today’s world, macular laser treatment has a vital role in the treatment of diabetic macular oedema (DMO). DMO is one of the most common causes of visual impairment. Despite expensive intravitreal treatment courses of anti-VEGF, many will agree that...Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting
The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...
